NA calls for prompt reimb of Ilaris during NA audit
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.10.18 17:05:24
가나다라
0
Improving the quality of life of pediatric patients... injected once every 8 weeks
HIRA President Jung-gu Kang “Deliberation of reimb standards set in September, will make efforts to reimburse the drug as soon as possible”
The National Assembly requested progress to be made in reimbursing ‘Ilaris (canakinumab, Novartis),’ a drug used to treat Hereditary recurrent fever syndromes that affect 13 patients in Korea.
Rep. Sun-Woo Kang of the Democratic Party of Korea and member of the National Assembly Health and Welfare Committee suggested so at the Health Insurance Service-Health Insurance Review and Assessment Service audit held on the 18th.
Mr. Lee, a parent of a pediatric patient whom Rep. Kang called as a witness, appeared before the National Assembly and said, "There are two palliative treatments. One is Kineret Inj, which needs to be administered daily, and my two-year-old child is suffering th
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)